Drugs /

inbrx-106

Back to Drugs List

Overview

NCI Definition [1]:
An agonistic, recombinant, humanized, hexavalent immunoglobulin G (IgG) antibody targeting the co-stimulatory receptor OX40 (CD134; tumor necrosis factor receptor superfamily member 4; TNFRSF4), with potential immunostimulatory and antineoplastic activities. Upon administration, anti-OX40 hexavalent agonist antibody INBRX-106 selectively binds to six OX40 receptors per molecule, thereby clustering and activating OX40. This induces the proliferation of memory and effector T-lymphocytes and results in a T-cell-mediated immune response against tumor cells, which leads to tumor cell lysis. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal that promotes both the proliferation and survival of activated T-cells. Utilizing a hexavalent OX40 antibody may improve receptor clustering and downstream signaling over tetravalent or bivalent OX40 antibodies.

Clinical Trials

View Clinical Trials for inbrx-106

Inbrx-106 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating inbrx-106, 1 is phase 1 (1 open).

EGFR A763_Y764insFQEA, EGFR Exon 19 Deletion, and EGFR Exon 19 Insertion are the most frequent biomarker inclusion criteria for inbrx-106 clinical trials.

Adenocarcinoma of the gastroesophageal junction, gastric adenocarcinoma, and head and neck squamous cell carcinoma are the most common diseases being investigated in inbrx-106 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Inbrx-106
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating inbrx-106 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
nbrx 106, es102, es-102, es 102, anti-ox40 hexavalent agonist antibody inbrx-106, anti-ox40 agonistic antibody inbrx-106, inbrx106
Drug Target(s) [2]:
TNFRSF4
NCIT ID [1]:
C173983

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.